Biopharma company Jazz Pharmaceuticals (NASDAQ: JAZZ) will be reporting earnings this Tuesday after the bell. Here’s what investors should know.
Jazz Pharmaceuticals missed analysts’ revenue expectations by 9% last quarter, reporting revenues of $897.8 million, flat year on year. It was a disappointing quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates.
Is Jazz Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Jazz Pharmaceuticals’s revenue to grow 2% year on year to $1.04 billion, slowing from the 6.9% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$6.25 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Jazz Pharmaceuticals has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Jazz Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Bristol-Myers Squibb posted flat year-on-year revenue, beating analysts’ expectations by 7.8%, and Merck reported a revenue decline of 1.9%, falling short of estimates by 1.1%. Bristol-Myers Squibb traded down 3.9% following the results while Merck was also down 2.7%.
Read our full analysis of Bristol-Myers Squibb’s results here and Merck’s results here.
The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Jazz Pharmaceuticals is up 2.2% during the same time and is heading into earnings with an average analyst price target of $186.12 (compared to the current share price of $110).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
